Status: Available
Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis
This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a clinical trial. The objective is to provide access to eRapa based on the treating physician's assessment that the potential benefits outweigh the potential risks, with appropriate clinical monitoring for safety and tolerability.
Trial details
Biological sex: AllType: Expanded AccessSponsor: Biodexa PharmaceuticalsUpdated: Jul 8, 2026
Eligibility criteria
Patient is post pubertal and reached full adult height [+2]
Patient has existing carcinoma or high-grade dysplasia in the GI tract and/or re... [+11]